New consensus guidance adapts NF1 diagnosis, surveillance and treatment to Singapore, with a stronger focus on plexiform tumours, transition to adult care and lifelong follow-up.
Singapore has published one of its first local consensus frameworks for neurofibromatosis type 1, a rare inherited disorder that can affect the skin, nervous system, bones, eyes and blood vessels. In an editorial accompanying the guidelines in the Annals, Fong and colleagues argue that NF1 care cannot simply be imported from elsewhere, because local referral routes, imaging access, drug availability and even patterns of disease may differ. That point is echoed by specialist centres in Singapore, which describe NF1 as a condition that requires early recognition, genetic assessment and coordinated care across disciplines.
The new recommendations were developed through a Delphi process that brought together geneticists, dermatologists, neurologists, neurosurgeons and oncologists. According to the authors’ description, the panel reviewed the literature, drafted more than 100 statements and then refined them through two rounds of anonymous scoring and discussion until a consensus threshold was reached. The result is an evidence-informed set of guidance covering diagnosis, surveillance in childhood, transition to adult care and the management of complications. For a disorder with few randomised trials, that kind of expert agreement is often the most practical way to turn limited evidence into usable clinical guidance.
A major focus of the Singapore document is plexiform neurofibroma, a tumour that can be difficult to remove completely and sometimes becomes cancerous. The panel supports surgery when it is feasible and recommends avoiding radiotherapy because of the risk of later malignancy and vascular damage. It also backs MEK inhibitors for symptomatic, inoperable or only partly resected tumours, reflecting a broader international shift towards targeted treatment. Trial data cited in the editorial show a meaningful but modest response in children and adults, which means access, cost and patient selection will remain important. In Singapore, selumetinib is already covered for some children through the Rare Disease Fund, and the editorial notes that adult access is less clear but not ruled out.
The stakes are high because NF1 can shorten life expectancy, largely through malignancy and vascular disease. The most serious cancer threat is malignant peripheral nerve sheath tumour, which often develops from pre-existing plexiform lesions. The Singapore guidance also places weight on whole-body MRI at the transition from adolescence to adulthood, suggesting a single scan between the ages of 16 and 20 to map hidden tumour burden. If no internal plexiform neurofibromas are found, repeated whole-body imaging is not routinely advised, but greater tumour burden justifies closer follow-up. The editorial says that this approach reflects a broader move away from concentrating surveillance only in childhood and towards planned monitoring across the lifespan.
The guidelines also address the wider burden of NF1, including pain, learning difficulties, attention deficit hyperactivity disorder, speech and language delay, scoliosis, osteoporosis, café-au-lait macules and hypertension. Just as importantly, they recommend psychological support as part of multidisciplinary care, recognising the condition’s effect on daily life and family wellbeing. The practical challenge now is not only making the recommendations available, but keeping patients in care. Specialist follow-up often falls away when paediatric services end, and Singapore data cited in the editorial suggest there is room to improve uptake of whole-body MRI surveillance. The authors also call for a formal transition pathway, a national registry and future guideline updates that include patient representatives, while acknowledging that issues such as cascade testing and reproductive counselling still need dedicated consensus work. For now, the Singapore guidance offers a workable foundation; the next task is to test, measure and refine it in practice.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
